- Home
- RVPHW vs EPRT Comparison
RVPHW vs EPRT Comparison
Compare RVPHW & EPRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPHW
- EPRT
- Stock Information
- Founded
- RVPHW N/A
- EPRT 2016
- Country
- RVPHW United States
- EPRT United States
- Employees
- RVPHW 15
- EPRT N/A
- Industry
- RVPHW Biotechnology: Pharmaceutical Preparations
- EPRT Real Estate Investment Trusts
- Sector
- RVPHW Health Care
- EPRT Real Estate
- Exchange
- RVPHW Nasdaq
- EPRT Nasdaq
- Market Cap
- RVPHW N/A
- EPRT N/A
- IPO Year
- RVPHW 2018
- EPRT 2018
- Fundamental
- Price
- RVPHW $0.17
- EPRT $31.70
- Analyst Decision
- RVPHW
- EPRT Strong Buy
- Analyst Count
- RVPHW 0
- EPRT 16
- Target Price
- RVPHW N/A
- EPRT $33.92
- AVG Volume (30 Days)
- RVPHW N/A
- EPRT 1.4M
- Earning Date
- RVPHW N/A
- EPRT 02-12-2025
- Dividend Yield
- RVPHW N/A
- EPRT 3.70%
- EPS Growth
- RVPHW N/A
- EPRT N/A
- EPS
- RVPHW N/A
- EPRT 1.15
- Revenue
- RVPHW N/A
- EPRT $428,535,000.00
- Revenue This Year
- RVPHW N/A
- EPRT N/A
- Revenue Next Year
- RVPHW N/A
- EPRT $19.41
- P/E Ratio
- RVPHW N/A
- EPRT $27.59
- Revenue Growth
- RVPHW N/A
- EPRT 27.83
- 52 Week Low
- RVPHW N/A
- EPRT $23.58
- 52 Week High
- RVPHW N/A
- EPRT $34.88
- Technical
- Relative Strength Index (RSI)
- RVPHW N/A
- EPRT 49.82
- Support Level
- RVPHW N/A
- EPRT $30.98
- Resistance Level
- RVPHW N/A
- EPRT $32.00
- Average True Range (ATR)
- RVPHW 0.00
- EPRT 0.70
- MACD
- RVPHW 0.00
- EPRT 0.09
- Stochastic Oscillator
- RVPHW 0.00
- EPRT 74.58
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.